ArticleAntibody therapeutics2025

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.

Chunyan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.